Search Results - "Krusch, Mathias"

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer by Rosen, David B, Kvarnhammar, Anne Månsson, Laufer, Burkhardt, Knappe, Thomas, Karlsson, Jens Jakob, Hong, Enping, Lee, Yu-Chi, Thakar, Dhruv, Zúñiga, Luis Alejandro, Bang, Kathy, Sabharwal, Simran Singh, Uppal, Karan, Olling, Janne Damm, Kjaergaard, Kristian, Kurpiers, Thomas, Schnabel, Meike, Reich, Diana, Glock, Philipp, Zettler, Joachim, Krusch, Mathias, Bernhard, Ana, Heinig, Stefan, Konjik, Valentino, Wegge, Thomas, Hehn, Yvonne, Killian, Steffen, Viet, Laura, Runz, Josefine, Faltinger, Frank, Tabrizi, Mohammad, Abel, Kristin Laura, Breinholt, Vibeke Miller, Singel, Stina M, Sprogøe, Kennett, Punnonen, Juha

“…BackgroundRecombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular…”
Get full text

Design and Preclinical Development of TransCon PTH, an Investigational Sustained‐Release PTH Replacement Therapy for Hypoparathyroidism by Holten‐Andersen, Lars, Pihl, Susanne, Rasmussen, Caroline E, Zettler, Joachim, Maitro, Guillaume, Baron, Julia, Heinig, Stefan, Hoffmann, Eric, Wegge, Thomas, Krusch, Mathias, Faltinger, Frank, Killian, Steffen, Sprogoe, Kennett, Karpf, David B, Breinholt, Vibeke Miller, Cleemann, Felix

“…ABSTRACT Hypoparathyroidism (HP) is a condition of parathyroid hormone (PTH) deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of…”
Get full text

TransCon IL-2 β/γ, a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog, demonstrates improved pharmacokinetics and profound expansion of cytotoxic immune cells in non-human primates by Rosen, David, Månsson Kvarnhammar, Anne, Olling, Janne Damm, Laufer, Burkhardt, Knappe, Thomas, Karlsson, Jens Jakob, Kurpiers, Thomas, Zettler, Joachim, Runz, Josefine, Faltinger, Frank, Viet, Laura, Krusch, Mathias, Schnabel, Meike, Reich, Diana, Glock, Philipp, Singel, Stina Mui, Sprogøe, Kennett, Abel, Kristin Laura, Breinholt, Vibeke Miller, Punnonen, Juha

“…2563 Background: Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe side effects including cytokine release…”
Get full text

Abstract 4507: TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer by Rosen, David Brian, Laufer, Burkhardt, Knappe, Thomas, Schnabel, Meike, Begaliew, Diana, Zettler, Joachim, Krusch, Mathias, Bernhard, Ana, Heinig, Stefan, Konjik, Valentino, Wegge, Thomas, Breinholt, Vibeke, Tabrizi, Mohammad, Sprogoe, Kennett, Punnonen, Juha

“…Background: Recombinant Interleukin-2 (IL-2, aldesleukin) is an approved immunotherapy for metastatic melanoma and renal cell carcinoma. However, treatment…”
Get full text